Edwards Lifesciences Corporation Stock
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.44 USD | -0.82% |
|
-0.06% | -0.95% |
| 01-22 | Leerink Partners Adjusts Edwards Lifesciences Price Target to $88 From $87, Maintains Market Perform Rating | MT |
| 01-22 | Venus Medtech Clarifies U.S. Patent Lawsuit Involving Subsidiary | MT |
| Capitalization | 49B 41.7B 38.73B 36.31B 67.62B 4,488B 71.69B 442B 175B 2,120B 184B 180B 7,758B | P/E ratio 2025 * |
37.2x | P/E ratio 2026 * | 30.8x |
|---|---|---|---|---|---|
| Enterprise value | 45.53B 38.75B 35.99B 33.74B 62.83B 4,170B 66.61B 411B 163B 1,970B 171B 167B 7,209B | EV / Sales 2025 * |
7.55x | EV / Sales 2026 * | 6.69x |
| Free-Float |
89.32% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Edwards Lifesciences Corporation
| 1 day | -0.82% | ||
| 1 week | -0.06% | ||
| Current month | -0.95% | ||
| 1 month | -2.42% | ||
| 3 months | +9.89% | ||
| 6 months | +10.67% | ||
| Current year | -0.95% |
| 1 week | 82.82 |  | 86.2 |
| 1 month | 81.26 | | 87.44 |
| Current year | 81.26 | | 86.6 |
| 1 year | 65.94 | | 87.89 |
| 3 years | 58.93 | | 96.12 |
| 5 years | 58.93 | | 131.73 |
| 10 years | 25.08 | | 131.73 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 11/05/2023 | |
Scott Ullem
DFI | Director of Finance/CFO | 59 | 01/01/2014 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 07/05/2024 | |
Kieran Gallahue
BRD | Director/Board Member | 62 | 10/02/2015 |
| Director/Board Member | 58 | 11/05/2023 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 2.46% | 54 M€ | |
| +0.75% | 2.34% | 26 M€ | |
| -0.31% | 1.17% | 25 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.82% | -0.06% | +22.31% | +6.50% | 49B | |
| +0.50% | +2.37% | +11.29% | +7.71% | 240B | |
| +0.40% | -2.87% | -13.87% | +104.78% | 186B | |
| -0.81% | +0.08% | -1.68% | -12.51% | 170B | |
| -0.46% | +1.40% | -8.99% | +100.11% | 135B | |
| -1.10% | -5.90% | -19.82% | -11.08% | 57.83B | |
| -0.82% | -4.28% | -9.15% | -11.09% | 39.3B | |
| -1.52% | -2.05% | +3.24% | +8.78% | 37.19B | |
| +0.97% | -0.75% | -6.23% | +22.64% | 37.3B | |
| -0.92% | -5.18% | -15.64% | -43.26% | 33.56B | |
| Average | -0.43% | -1.57% | -3.85% | +17.26% | 98.58B | |
| Weighted average by Cap. | -0.15% | -0.51% | -2.46% | +32.23% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 6.03B 5.13B 4.77B 4.47B 8.32B 553B 8.83B 54.44B 21.57B 261B 22.62B 22.16B 955B | 6.62B 5.63B 5.23B 4.9B 9.13B 606B 9.68B 59.71B 23.66B 286B 24.81B 24.3B 1,048B |
| Net income | 1.32B 1.12B 1.04B 976M 1.82B 121B 1.93B 11.88B 4.71B 56.97B 4.94B 4.84B 208B | 1.58B 1.34B 1.25B 1.17B 2.18B 144B 2.31B 14.23B 5.64B 68.24B 5.91B 5.79B 250B |
| Net Debt | -3.47B -2.95B -2.74B -2.57B -4.79B -318B -5.08B -31.32B -12.41B -150B -13.01B -12.75B -549B | -4.74B -4.03B -3.75B -3.51B -6.54B -434B -6.93B -42.77B -16.95B -205B -17.77B -17.41B -750B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 84.44 $ | -0.82% | 3,821,534 |
| 21/01/26 | 85.14 $ | +2.01% | 5,043,279 |
| 20/01/26 | 83.46 $ | -1.06% | 4,000,794 |
| 16/01/26 | 84.35 $ | -0.17% | 3,454,404 |
| 15/01/26 | 84.49 $ | +1.67% | 3,103,907 |
Delayed Quote Nyse, January 23, 2026 at 01:00 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EW Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition